Oral pantothenic acid as the sole active ingredient,
does it really help with Reduction of FSS fatigue severity in adults with unexplained/nonspecific persistent fatigue?
research showsWithin the recorded search scope, no directly eligible between-group result was verified showing that oral pantothenic acid alone lowers FSS fatigue severity versus placebo/usual care on matched background treatment. ? denotes the current evidence-verification state, not no effect or worldwide absence of research. Related human studies exist but test mixtures, specific diseases or other endpoints. [S201][S202][S205][S207]
ads claimMetabolic/CoA roles, blood markers, exercise performance, vitality/mood or case improvements in another disease do not replace this fatigue-treatment outcome. Pantethine, pantetheine, dexpanthenol/panthenol, B-complex products, multivitamins and multi-active energy products are not the same intervention. [S06][S210][S213][S216]
Four separate assessment dimensions
| Effect direction and size | No directly eligible between-group FSS result for pantothenic-acid monotherapy verified |
|---|---|
| Evidence certainty | ? is scoped direct-evidence uncertainty, not no effect |
| Applicability | Adults with unexplained nonspecific persistent fatigue; oral pantothenic acid as the sole active ingredient; placebo or usual care on matched background treatment |
| Safety | Caution |
B / P / null / null / null / null / null; score and strength count null
Useful facts when choosing a product
- The origin, exact salt, brand, purity, batch, formulation, release type, dose, frequency, duration and adherence of an eligible monotherapy are not verified.
- Calcium pantothenate requires salt-specific verification; a conversion reported for another product is not transferred. [S06][S213]
- Placebo composition, common care, rescue treatment, baseline nutrition/deficiency and the fatigue-duration threshold are not verified in an eligible monotherapy trial.
Chamgap Semantic Classification Code
Permanent code issued
S.pantothenic-acid.oral.nonspecific-persistent-fatigue-fss.reduce.placeboSubstances and nutrients > Pantothenic acid (vitamin B5), sole active ingredient > Oral > FSS severity in unexplained nonspecific persistent fatigue > Reduction claim > Placebo
Bound to FSS severity in adults with unexplained nonspecific persistent fatigue. Mixed products, disease-specific fatigue such as CFS or lupus, and other fatigue scales remain separate boundaries. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Pantothenic acid (vitamin B5), sole active ingredient; exact salt separately verified |
| Source or part used | Not verified — origin, purity and batch of an eligible monotherapy |
| Formulation or processing | Single-active oral formulation; exact salt, tablet/capsule and release type not verified |
| Route | Oral |
| Dose | Not verified — eligible monotherapy dose and frequency |
| Duration | Not verified — eligible monotherapy duration and assessment time |
| Population | Adults with unexplained/nonspecific persistent fatigue, separated from specific diseases and deficiency correction |
| Effect or condition | Reduction of persistent fatigue severity |
| Primary endpoint | FSS between-group change preferred; endpoint difference separate; eligible-trial version, scoring and timing not verified |
| Comparator | Placebo or usual care on the same background treatment; actual composition and concomitant care not verified |
| Duplicate-detection key | oral|pantothenic-acid|sole-active|salt=UNK|nonspecific-persistent-fatigue-adults|FSS|change|time=UNK|dose=UNK|matched-placebo-or-usual-care |
What the research actually shows
The lupus fatigue narrative is not direct evidence either. The verified 2007 report describes 12 women receiving calcium pantothenate 10 g/day together with several other vitamins and combination tablets. No comparator and validated-fatigue-score between-group result were verified. Possible participant overlap with the 2004 report was unresolved, so samples were not added, and calcium-salt mass was not converted to pantothenic-acid mass. [S206][S207]
Why this is classified as ?
The original rubric and calculator produce ? with a null score at stage 0. The 7 axes are B / P / null / null / null / null / null. Fatigue severity is patient-reported treatment target P; the remaining five axes and strength count are unscored, not 0. No score is inherited from a related mixture or an earlier verdict.
Counterpoint. The actual FSS version, range, scoring and assessment time, arm-specific allocation/analysis/completion counts, baseline/change/endpoint values, between-group effect, CI, P value and MCID are not verified for the primary question. CIS was not converted to FSS, and graphs, correlations or variances were not reconstructed. Inaccessible registrations or papers were not counted as negative studies. [S201][S205][S214][S215]
Rejudgment record. No directly eligible between-group result verified — Original rubric stage 0; subsequent axes unscored
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
Stored derived and displayed grades match; this is not a current recalculation or validity check (?).
Review performed and remaining limitations
Directly eligible monotherapy results, salt, formulation, dose, duration, population criteria, FSS version/timepoint and between-group effect, CI, P value and denominator remain unverified
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ullah 2023 trial of pomegranate extract, B-complex vitamins and vitamin C | Mixed-product placebo-controlled randomized trial | 58 randomized, 29 per arm; FSS analysis denominators and completion count unverified | Esserre product with a company employee among the authors; full funding and patent details unverified | Ineligible for the direct monotherapy FSS question | FSS improvement reported; B5 contribution cannot be isolated | Excluded from direct grading |
| Brouwers 2002 trial of a polynutrient supplement in CFS | CFS polynutrient randomized trial | 53 randomized (27/26) and 48 completed; not a pantothenic-acid monotherapy FSS denominator | Numico supplied/manufactured the product and an author had a Numico affiliation; exact funding details unverified | Ineligible for the direct monotherapy FSS question | No significant group difference reported in CIS and other outcomes; not B5-only evidence of no effect | Excluded from direct grading |
| Uncontrolled multiple-vitamin case series in patients with lupus | Lupus multiple-vitamin case series | 12 women; no concurrent comparator or validated FSS | Funding, product supply and patent relevance unverified | Ineligible for the direct monotherapy FSS question | Subjective fatigue narrative; comparator/validated scale absent or unverified | Excluded from direct grading |
| ACTRN12613001087741 registered multicomponent multivitamin trial | Registered multicomponent trial | Healthy women aged 50–75; actual randomized count and results unverified | Swisse-branded product; complete sponsorship and financial conflicts were not reviewed for an efficacy conclusion | Ineligible for the direct monotherapy FSS question | Different population and secondary Chalder endpoint; not B5-only results | Excluded from direct grading |
Receipt — 18 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Cite this verdict
[Chamgap] Oral pantothenic acid alone × nonspecific persistent fatigue severity — Evidence Grade ?. 18 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/pantothenic-acid-monotherapy-nonspecific-persistent-fatigue-fss/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.